ONL Therapeutics | Advancing Retinal Disease Therapies through Neuroprotection

News

ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones

January 13, 2022
ONL Therapeutics Names Connie Chang as Chief Operating Officer

January 19, 2021
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications

December 22, 2020
ONL Therapeutics featured on the OIS Retina Podcast

June 30, 2020
ONL Therapeutics Announces First Patient Treated in Phase I Study With ONL1204

October 23, 2019
ONL Therapeutics Announces First-in-human Clinical Study With ONL1204

October 8, 2019
ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 Into First-in-Human Clinical Study

August 22, 2019
ONL Therapeutics Names Industry Veteran as CEO as Company Prepares for First In Human Clinical Trials

June 18, 2019
ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases

May 17, 2017

Privacy Statement | Accessibility Statement | Terms of Use | Copyright All Rights Reserved ©2025